Search
for
Sort by
Research 331–360 of 338
- Carcinogenesis of the Human Scalp. An Immunometabolic Centered View
- FREQUENCY OF DYSLIPIDEMIA IN MALE PATIENTS PRESENTING WITH ANDROGENIC ALOPECIA AT TERTIARY CARE HOSPITAL, KARACHI
- Clinical, Dermoscopic, and Histological Characteristics of Melanoma Patients According to the Age Groups: A Retrospective Observational Study
- Synthetic Approaches for Pharmacologically Active Decorated Six-Membered Diazines
- Reexamining the Role of Diet in Dermatology
- Alopecia
- Keratosis pilaris
- 801 TEC family kinase inhibitors as a novel class of therapeutics in alopecia areata
- 696 MEK and BRAF inhibitors augment the production and accumulation of sebum in hamster sebocytes
- Diseases of the Canine Prostate Gland
- 554 Repurposing a clinical antimalarial for the therapeutic induction of lethal ER stress targeting BRAF-kinase inhibitor-resistant malignant melanoma
- The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma
- BRAF Inhibitor Dabrafenib in Patients with Metastatic <i>BRAF</i>-Mutant Thyroid Cancer
- Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
- Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis
- Diagnosis and Management of Melanoma of the Scalp: A Review of the Literature
- Cutaneous toxicities of new treatments for melanoma
- Is knowledge about the genetic and epigenetic alterations in melanoma a basis for targeted therapy?
- Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
- Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells
- Logic-based modeling and drug repurposing for the prediction of novel therapeutic targets and combination regimens against E2F1-driven melanoma progression
- Biological therapy in the treatment of melanoma
- Endocrine treatment of benign prostatichypertrophy: Current concepts
- Lentiginous melanoma. A clinically malignant entity that histopathologically seems benign. Case study harbouring BRAF V 600R mutation
- LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1.
- Redefining hormone resistance in prostate cancer
- The PDGF/PDGFR pathway as a drug target
- Male androgenetic alopecia (Part II)